First Survival Results With Immunotherapy, TNBC – Medscape
TIME |
First Survival Results With Immunotherapy, TNBC
Medscape WASHINGTON, DC — The proportion of patients with metastatic triple-negative breast cancer who respond to the immunotherapy atezolizumab (Tecentriq, Genentech) is only 10% to 13%, but the responses tend to last a long time, according to new results … Triple-negative Breast Cancer Patients Who Responded to Immunotherapy Had Long-term Survival Benefit Atezolizumab Yields Long-Term OS in mTNBC Subset |
